Seattle biotech startup OncoSenX has reeled in $3 million to advance its pipeline of therapeutics that aim to kill cancer cells based on their genetics. OncoSenX’s technology targets solid tumors based on a patented lipid nanoparticle gene delivery system and a highly targeted DNA payload. The company claims that its approach is “a less invasive, more precise intervention” of cancer therapy. OncoSenX is a spinout out of Oisin Biotechnologies, a 5-year-old Seattle company led by veteran biotech entrepreneur Matthew Scholz, who is CEO of OncoSenX.